



ORIGINAL ARTICLE

Lack of almagate interference in breath test results for *Helicobacter pylori* diagnosis (Almatest study)[☆]



Carles Pons^{a,*}, Modesto Varas^b, Javier P. Gisbert^c, Mercè Barenys^d, Francesca Pajuelo^e, Francisco Javier Fernández^e

^a Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospital de Viladecans, Barcelona, Spain

^b Hospital CIMA Sanitas, Barcelona, Spain

^c Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

^d Centro Médico Teknon, Barcelona, Spain

^e Compañía farmacéutica Almirall, S.A., Barcelona, Spain

Received 9 July 2020; accepted 22 October 2020

Available online 22 September 2021

KEYWORDS

Urea breath test;
UBT;
Helicobacter pylori;
Dyspepsia;
Antacids;
Almagate

Abstract

Objective: The 13C-urea breath test (UBT) is the most widely used non-invasive diagnostic test for *Helicobacter pylori*. Debate continues to surround the possible interference of antacid intake on its result. This study aims to confirm the non-interference of almagate in the determination of *H. pylori* by UBT.

Patients and methods: Observational, multicentre study in adult patients treated with almagate in whom a UBT (TAUKIT[®]) was indicated. When the UBT result was negative, use of almagate was stopped for 30 days and the UBT was repeated. When the result was positive, no further determinations were made. The primary endpoint was the percentage of patients who, having had a negative result in the first breath test, were positive in the second after having stopped taking almagate (UBT false negatives, possibly attributable to almagate).

Results: Of the 167 evaluable patients, 59% were female, average age was 49 and 97% had gastrointestinal symptoms. The result of the first UBT was negative in 71% of cases. Of these, in the second UBT test after stopping the almagate, the negative result was confirmed in 97.5%. Out of the total number of cases evaluated, the rate of false negatives was 1.8%.

Conclusions: Taking almagate has minimal or no interference in the result of UBT for the diagnosis of *H. pylori* infection. It can therefore be used in the weeks prior to a UBT.

© 2021 The Author(s). Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

[☆] Please cite this article as: Pons C, Varas M, Gisbert JP, Barenys M, Pajuelo F, Fernández FJ. Ausencia de interferencia de almagato en los resultados de la prueba de aliento para el diagnóstico de *Helicobacter pylori* (estudio Almatest). Gastroenterol Hepatol. 2021;44:628–636.

* Corresponding author.

E-mail address: cpvilardell.hv@gencat.cat (C. Pons).

PALABRAS CLAVE

Test de aliento de urea;
TAU;
Helicobacter pylori;
Dispepsia;
Antiácidos;
Almagato

Ausencia de interferencia de almagato en los resultados de la prueba de aliento para el diagnóstico de *Helicobacter pylori* (estudio Almatest)

Resumen

Objetivo: El test del aliento con ^{13}C -urea (TAU) es la prueba no invasiva más utilizada para diagnosticar *Helicobacter pylori* (*H. pylori*). La posible interferencia de la toma de antiácidos en su resultado es aún controvertida. El estudio se dirige a confirmar la no interferencia del almagato en la determinación de *H. pylori* mediante el TAU.

Pacientes y métodos: Estudio observacional, multicéntrico, en pacientes adultos en tratamiento con almagato y a los que se indicó un TAU (TAUKIT®). Cuando el resultado del TAU fue negativo, se suprimió la toma de almagato durante 30 días y se repitió un segundo TAU. En los pacientes cuyo resultado fue positivo, no se realizaron más determinaciones. La variable principal a estudio fue el porcentaje de pacientes que teniendo resultado negativo en la primera prueba de aliento, tras suprimir la toma de almagato y repetirla, ésta se positivizó (falsos negativos del TAU, posiblemente atribuibles a almagato).

Resultados: De los 167 pacientes evaluables, 59% fueron mujeres, la media de edad fue de 49 años y 97% de los casos presentaban sintomatología digestiva. El resultado del primer TAU fue negativo en un 71% de casos. De éstos, en la segunda prueba de TAU tras suprimir almagato, este resultado se confirmó en el 97,5%. El porcentaje de falsos negativos sobre el total de casos evaluados fue del 1,8%.

Conclusiones: La toma de almagato tiene una interferencia mínima o nula en el resultado del TAU para el diagnóstico de la infección por *H. pylori*; por tanto, se puede utilizar en las semanas previas a la realización del TAU.

© 2021 El Autor(s). Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY (<http://creativecommons.org/licenses/by/4.0/>).

Introduction

Although recent data indicate that infection with *Helicobacter pylori* (*H. pylori*) has been waning in recent years, it is still highly prevalent globally¹, affecting one third of the population of North America and Europe and up to 50% of the population of Southern and Eastern Europe and Asia.²

In Spain, approximately 50% of the general population is believed to be infected³, the prevalence being higher in some communities (up to 60% in the Community of Madrid)⁴, and especially in patients who consult for dyspepsia (67%).⁵

Diagnostic tests for *H. pylori* infection can be invasive, i.e. requiring an endoscopy, or non-invasive. The most widely used non-invasive test is the ^{13}C -urea breath test (UBT), based on the urease activity of *H. pylori* and offering high diagnostic precision.⁵

However, previous studies have revealed frequent UBT false negatives, the most common causes being that the patient has received treatment with antibiotics⁶ or proton pump inhibitors (PPIs).⁷ Therefore, PPI treatment should be suspended two weeks before the test.⁷ The results regarding histamine H_2 -receptor antagonists (H_2 blockers) are controversial, although they mostly show evidence of not affecting, or minimally affecting, the UBT's accuracy.⁸

PPIs are widely used for the treatment of dyspepsia and reflux⁹, although for symptomatic management (heartburn), antacids such as almagato¹⁰, indicated in adults and children over 12 years¹¹ are often used. Understanding the possible interference of antacids in the UBT is important, both so that they can be avoided before the test is performed, in case they interfere, and so that they can be used

as a possible alternative to PPIs in the weeks prior to the UBT if they do not interfere.

In a preliminary study carried out by our group in 30 patients, the use of almagato did not interfere with the UBT results.¹² This study's primary variable was to confirm that the use of almagato does not interfere in the determination of *H. pylori* by UBT. Whether or not almagato interferes in certain clinical situations or subgroups of patients was also analysed.

Patients and methods

This was an observational, multicentre, post-authorisation study carried out in 10 Spanish gastroenterology departments, under the usual medical and clinical practice conditions.

Patients of both sexes over 18 years of age who were scheduled to take the UBT test and were undergoing treatment with almagato for 30 days at a dose of 1.5 g of almagato oral suspension every 12 h and up to 24 h before the UBT participated. Pregnant or breast-feeding patients, those on treatment with PPIs or antibiotics in the 30 days before the UBT, or those who in the investigator's opinion were unable to meet the study requirements were excluded.

The UBT was conducted with the 100 mg ^{13}C -urea TAUKIT® kit (Isomed Pharma) containing a solution enriched with citric acid.⁵ The samples were analysed in a centralised reference laboratory in Madrid. The cut-off point was 5 per 1000; hence, when the difference of the value of the $^{13}\text{C}/^{12}\text{C}$

ratio between baseline and 30 min was $>5^\circ/_{00}$ it was considered positive for *Helicobacter* infection.

The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practices and was approved by the Clinical Research Ethics Committee (CREC) of the Hospital Universitario de Bellvitge [Bellvitge University Hospital] [EPA010/14 approved on 08/05/2014]. All patients provided their written consent.

Description of the study

During the first visit in which the first UBT was performed, the reason for the indication of the UBT, the data regarding the treatment with almagate (administration date and dosage), and other treatments for digestive diseases or other concomitant pathologies were collected. Similarly, sociodemographic (sex, age, height, weight, BMI, race) and clinical data (gastric symptoms, history of gastric pathology and time since diagnosis, family history of gastric cancer) were collected. If the result of this first test was negative, the patient refrained from taking almagate and the test was repeated at a second visit 30 days later (Fig. 1). A patient was considered to have had a false negative result if they obtained a negative result in the first UBT and a positive result in the second.

All the analyses were carried out from a single sample of evaluable patients that included all those who met the selection criteria and the protocol in order to be able to analyse the study's primary variable. This variable was defined as the percentage of patients with a negative result in the first UBT who were positive in the second after having stopped taking almagate (false negatives in the first UBT). These patients were classified according to the result obtained in the second test.

The analysis of the secondary variables allowed the patients to be characterised according to the UBT result. The aforementioned descriptive biodemographic and clinical variables, the details of the almagate treatment, pathologies and concomitant treatments were compared using percentages or means depending on the nature of the variable.

Statistical analysis

The calculation of the sample size was based on the study's main hypothesis, which was to evaluate the non-interference of almagate in the ^{13}C -urea breath test result. A pilot study¹² carried out in a short series of patients detected a negative result in 51.9% of cases; the negative result was confirmed in all of them (100%) when the test was repeated one month after the withdrawal of almagate. The proportion of patients with UBT false negatives performed in two tests was estimated from the binomial distribution, with a 95% confidence interval estimated. A sample size of 182 patients would yield a precision of $\pm 7.5\%$ to estimate the proportion of patients with UBT false negatives performed in two tests with a 95% confidence interval. Assuming 10% of patients that were not valid for analysis, approximately 200 patients needed to be recruited. The calculations were made with the help of the PASS program, 2011 version.

192 patients were recruited, 25 of whom were excluded: one for having been treated with a PPI in the 30 days before the UBT, seven for not having taken almagate as per the protocol (minimum of 25 days before the UBT), and 17 for not having performed the second breath test in the cases required by the protocol. Thus, the final evaluable sample was 167 patients (87% of the patients recruited).

Since there were ultimately 167 evaluable patients for the analysis, the proportion of patients with UBT false negatives was estimated with a precision of $\pm 7.8\%$, considering that the proportion of negatives is equal to the proportion calculated in the sample size (51.9%).

The confidence intervals (95% CI) for the proportions of patients were calculated with the Wilson method.

The qualitative variables were described using absolute and relative frequencies and the continuous variables using the mean, standard deviation, median, minimum and maximum, including the total number of valid values.

For the comparison of subgroups of patients in the quantitative variables, the parametric Student's *t* test or the non-parametric Mann-Whitney *U* test was used according to characteristics of normality of the variables. For the qualitative variables, the χ^2 test was performed or, if the necessary conditions were not fulfilled, Fisher's exact test. A level of statistical significance of 0.05 was applied in all the statistical tests.

Results

Demographic and clinical data

The data are shown in Table 1. Mean age was 48.7 years, 59.3% were women and 79.6% were Caucasian.

The indication for performing the breath test was a previous diagnosis of *H. pylori* infection in 38.9% ($n=65$) of the patients. Of these 65 participants, the diagnosis had been made by breath test in 37 and by endoscopic biopsy in the remaining 28. In the rest, 63.5% ($n=106$), the test was performed to ascertain whether or not they were infected for different clinical reasons.

97% of the evaluable patients had presented digestive symptoms, the most common symptoms being dyspepsia (52.7%) and reflux (31.7%). Five patients did not present any digestive symptoms.

In almost half of the patients (49.7%) there was a previous diagnostic certainty of digestive pathology, with a mean time since diagnosis of 2.4 years (± 4.7), the most common diagnoses being gastritis (20.9%) and reflux or hiatal hernia (18.6%). The other half (50.3%) without a previous diagnosis of digestive disease was included to study uninvestigated dyspepsia more thoroughly or because they had a family history of gastric cancer (12.6% of cases) or *H. pylori* infection. A small number of patients were included because of their own desire to find out if they were carriers of the infection.

Concomitant pathologies were described in 15% of patients, the most common being cardiovascular disorders (3.6%), followed by liver disorders and endocrine disorders (2.4% in both cases).




Figure 1 Study design. UBT ¹³C-urea breath test.

Treatments

The mean time from the start of almagate treatment to the first UBT was 1.1 months (± 1.0). All the evaluable patients received almagate for a minimum of 25 days prior to the UBT, with a mean of 29.9 days. 97% of the patients took the doses described in the protocol (1.5 g/12 h) and the remaining 3% took a lower (1.5 g/24 h) (four cases) or higher (1.5 g/8 h) (one case) dose.

Only two patients who had reported having a digestive disease were receiving any treatment for it at the time of the UBT or within the previous 30 days. One patient was taking loperamide and the other omeprazole (in this case before the second UBT).

Regarding other associated non-digestive pathologies, 22.2% of the patients evaluated stated that they were receiving concomitant treatment at the time of the UBT. Antihypertensive drugs (5.4%) and systemic hormonal preparations (levothyroxine 4.8%) were the most common, followed by lipid-lowering drugs (4.2%) and antidepressants (3.6%). It should be noted that three patients (1.8%) were taking ranitidine.

UBT results

The mean time between the first and second test was 48.5 days (± 26.4), with a median of 38.5 days.

70.7% (95% CI: 63.4%; 77%) of the patients had a negative result in the first breath test. Of these, the second test confirmed the negative result in 97.5% (95% CI: 92.8%; 99.1%),

and it was positive (false negatives) in 2.5% (95% CI: 0.9%; 7.2%) (Table 2). The proportion of false negatives out of the total number of patients evaluated ($n = 167$) was 1.8% (95% CI: 0.6%, 5.1%).

After the groups had been analysed and modified with the study's false negatives, the final results were 115, or 68.9%, uninfected patients (95% CI: 61.5%; 75.4%), and 52, or 31.1%, infected patients (95% CI: 24.6%; 38.5%) (Table 3).

Of these 52 infected patients, 13 belonged to the group previously diagnosed with *H. pylori*, hence the prevalence of infection in this group was 20% (95% CI 12.1, 31.3) (13/65), and 39 belonged to the group that had not been diagnosed, hence the prevalence of infection in this other group was 38.2% (95% CI 29.4; 47.9) (39/102).

UBT result in terms of other variables

No statistically significant differences were observed in the UBT result in relation to demographic characteristics, history of previous digestive pathology, other associated diseases or concomitant treatments.

No statistically significant differences were observed for any of the digestive symptoms based on the UBT result (χ^2 test; Fisher's exact test; $p > 0.05$) (Table 4). Five patients (three with a positive result and two with a negative result) did not present any symptoms of dyspepsia.

One of the 118 patients with a negative result in the first test indicated that they had received omeprazole in the period before the second UBT; the negative result in this

Table 1 Sociodemographic and clinical characteristics.

	n = 167
Sex (woman)	99 (59.3)
Age (years)	48.7 ± 14.5
Weight (kg)	70.3 ± 12.1
Height (cm)	167.0 ± 8.0
BMI (kg/m ²)	25.1 ± 3.5
Race	
Caucasian	133 (79.6)
Hispanic	32 (19.2)
African American	2 (1.2)
*Gastric symptoms	162 (97)
Dyspepsia	88 (52.7)
Heartburn	53 (31.7)
Abdominal pain	26 (15.6)
Isolated nausea	13 (7.8)
Gastroenteritis	1 (0.6)
°Other GI symptoms	12 (7.2)
*Previous gastric pathology	83 (49.7)
Time since diagnosis (years)	1 [0; 30.4]
^b Nonerosive gastritis ± <i>H. pylori</i>	35 (20.9)
^c Reflux or hiatal hernia	31 (18.6)
^d Ulcer disease	18 (10.8)
Functional dyspepsia	9 (5.4)
Abdominal/diverticular pain and irritable bowel synd.	3 (1.8)
Gastric cancer	1 (0.6)
Gastric polyps	1 (0.6)
Crohn's disease	1 (0.6)
Family history of gastric cancer	21 (12.6)
*Concomitant pathology	25 (15)
Cardiovascular diseases	6 (3.6)
Liver diseases	4 (2.4)
Endocrine diseases: hypothyroidism	4 (2.4)
Haematological diseases	3 (1.8)
Infectious diseases	1 (0.6)
Respiratory diseases	2 (1.2)
^e Others	9 (5.4)

BMI: body mass index; GI: gastrointestinal; *H. pylori*: *Helicobacter pylori*.

Quantitative data expressed as mean ± SD or median [min; max] and qualitative as n (%).

* The same patient can present more than one symptom, medical history or pathology simultaneously.

^a Flatulence (n = 5), gastroesophageal reflux disease (n = 3), diarrhoea (n = 1), bloating (n = 1), upper gastrointestinal bleeding (n = 1), salivary hypersecretion (n = 1), halitosis (n = 1), vomiting (n = 1).

^b Gastritis (n = 11), chronic gastritis (n = 5), metaplasia (n = 1), isolated *H. pylori* infection (n = 18).

^c Reflux includes Barrett's oesophagus (n = 1), hiatal hernia (n = 2) and oesophagitis (n = 28).

^d Duodenal ulcer (n = 2), erosive duodenitis (n = 4), gastric ulcer (n = 9), erosive gastritis (n = 3).

^e Abnormal lipids, prostate disorder, diabetes mellitus, dyslipidaemia, hypersensitivity, dysplasia, back pain, depression, hypertension (n = 1 of each).

case was confirmed in the second breath test, which is why it was not excluded for evaluation.

Treatment with almagate according to the UBT result

No statistically significant differences were observed in the UBT result (Mann-Whitney *U* test; *p* > 0.05) in terms of the duration of previous treatment with almagate or the dosage, according to the UBT result (Fisher's exact test; *p* > 0.05).

Discussion

The prevalence of *H. pylori* infection in Spain is high and is similar to that of other southern European countries², reaching 65% in patients with dyspepsia.¹³

Dyspepsia is a very prevalent condition that affects 20%–25% of western populations.^{14,15} In the population aged <50–55 years and without warning signs, the recommended initial management is the "test and treat" strategy, which involves a non-invasive test for *H. pylori* followed by eradication therapy in positive cases.¹⁶

In general, the diagnostic accuracy of the UBT is good, with a sensitivity and specificity >95% in most cases.⁵ Different techniques are used to perform it, and the one used in this study includes citric acid. The cut-off point established is five units, and its sensitivity is 96% (which indicates that there is a small percentage of false negatives). Its specificity is 100% and the positive (PPV) and negative (NPV) predictive values are 100 and 92%¹⁷, respectively.

The breath test without citric acid¹⁸ and stool antigen test for *H. pylori*¹⁹ have a lower sensitivity but good specificity for *de novo* diagnosis of *H. pylori*. However, the stool antigen test has a significant false positive rate when used for post-eradication monitoring.²⁰

The data obtained in our study, with a sensitivity of 94.2% (95% CI: 84.4%; 98%), a specificity of 100% (95% CI not calculable) and high predictive values [PPV: 100% (95% CI not calculable) and NPV: 97.5% (95% CI: 92.8%; 99.1%)] (Table 3), as was to be expected in areas with a high prevalence of infection, are similar to those of the technique's reference study.¹⁷ The apparent greater sensitivity [96% (95% CI: 81%; 99%)] of the reference study may be due to the fact that in this case the UBT results were confirmed with two other diagnostic tests and, when they were discordant, which was the case in three patients, they were excluded from the sensitivity and specificity calculations.¹⁷ In any case, the confidence interval of the sensitivity of our study is included within the CI of the sensitivity of the reference study.

According to the NPV, the probability of not having *H. pylori*, if the UBT result is negative, is almost 98%, meaning that when the test result is negative there is still a 2% chance of actually being infected and going undiagnosed (NPV-1). The 95% CI range (92.8%; 99.1%) indicates that in the population treated with almagate the probability of going undiagnosed can vary from 0.9% to 7.2%.

Table 2 UBT results.

	n	%	%*
UBT test 1	167	100	–
Positive	49	29.3% (23%; 36.6%)	–
Negative	118	70.7% (63.4%; 77%)	–
UBT test 2	118	70.7	100
Positive	3	1.8% (0.6%; 5.1%)	2.5% (0.9%; 7.2%)
Negative	115	68.9% (61.5%; 75.4%)	97.5% (92.8%; 99.1%)

Data in brackets indicate the 95% confidence interval.

UBT: ¹³C-urea breath test.

* Percentages calculated out of the total number of patients with a negative result in the first test (n = 118).

Table 3 Total infected and non-infected patients.

1st UBT	Infected	Non-infected	Total
Positive	49	0	49
Negative	3	115	118
Total	52	115	167

UBT: ¹³C-urea breath test.

Sensitivity: 49/52 = 0.94; 94.2% (95% CI: 84.4%, 98.0%).

Specificity: 115/115 = 1; 100% 95% CI Not calculable.

Positive predictive value (PPV): 49/49 = 1; 100% 95% CI Not calculable.

Negative predictive value (NPV): 115/118 = 0.97; 97.5% (95% CI: 92.8%; 99.1%).

Table 4 Gastric symptoms and history according to UBT result.

	UBT	
	Positive n = 52	Negative n = 115
*Gastric symptoms	49 (94.2%)	113 (98.3%)
Dyspepsia	25 (48.1%)	63 (54.8%)
Abdominal pain	7 (13.5%)	19 (16.5%)
Isolated nausea	2 (3.8%)	11 (9.6%)
Heartburn	17 (32.7%)	36 (31.3%)
Gastroenteritis	0 (0%)	1 (0.9%)
^a Other GI symptoms	5 (9.5%)	9 (7.8%)
*History of gastric pathology	21 (40.4%)	62 (53.9%)
^b Nonerosive gastritis ± <i>H. pylori</i>	12 (23.1%)	23 (20%)
^c Reflux or hiatal hernia	7 (13.5%)	24 (20.9%)
^d Ulcer disease	3 (5.8%)	15 (13%)
Functional dyspepsia	1 (1.9%)	8 (6.9%)
Abdominal/diverticular pain and irritable bowel syndrome	0	3 (2.6%)
Gastric cancer	0	1 (1.9%)
Gastric polyps	1 (1.9%)	0
Crohn's disease	1 (1.9%)	0
*Family history of gastric cancer	5 (9.6%)	16 (13.9%)

UBT: ¹³C-urea breath test; GI: gastrointestinal; *H. pylori*: *Helicobacter pylori*.

* χ^2 test; Fisher's exact test; p > 0.05.

^a Flatulence (n = 5), gastroesophageal reflux disease (n = 3), diarrhoea (n = 1), bloating (n = 1), upper gastrointestinal bleeding (n = 1), salivary hypersecretion (n = 1), halitosis (n = 1), vomiting (n = 1).

^b Gastritis (n = 11), chronic gastritis (n = 5), metaplasia (n = 1), isolated *H. pylori* infection (n = 18).

^c Reflux includes Barrett's oesophagus (n = 1), hiatal hernia (n = 2) and oesophagitis (n = 28).

^d Duodenal ulcer (n = 2), erosive duodenitis (n = 4), gastric ulcer (n = 9), erosive gastritis (n = 3).

Different drugs can interfere with the UBT result. Antibiotics can cause false negatives⁶, so it is recommended that they be avoided for at least four weeks before the UBT is performed.²¹

PPIs are the most widely used drugs in the treatment of dyspepsia and *H. pylori*.¹¹ However, their use is associated with a decrease in the survival of the *Helicobacter* and its urease activity²², which can lead to false negatives. Therefore, the UBT test is not reliable if it is performed within two weeks of stopping treatment with PPIs.^{7,21,22} One of the patients with a negative result in the first test had received omeprazole in the period before it was performed; however, the negative result was confirmed. Omeprazole is documented as one of the PPIs that interfere with UBT²², although some works have suggested that the false negative rate is lower than with other PPIs.²³

The impact of H₂ blockers, such as ranitidine, on the UBT result is controversial^{24,25}; however, it seems not to interfere, or any interference is of scant relevance.^{24,26} There are differences in the results between studies that analyse the possible interference of H₂ blockers with UBT, which may be attributable to both the duration of the previous treatment with H₂ blockers as well as to questions inherent in the actual UBT test (whether it includes citric acid, what the dose is and what the cut-off point is).²⁶ Regarding antacids, their mechanism of action consists of alkalinising and neutralising the acid accumulated in the stomach²⁷ and they have no known activity against *H. pylori*. While it has been asserted that antacids do not interfere with the sensitivity of *H. pylori*²⁸ breath tests, few studies have been performed to confirm this. Almagate is one of the most widely used antacids¹⁰ and is indicated for the relief and symptomatic treatment of stomach acidity and heartburn in adults and children over 12 years.¹¹ In a pilot study in 27 patients, infection was ruled out in 14 in the initial UBT and negativity was confirmed in all cases following the suspension of almagate; i.e. no false negatives were observed. In this study, conducted with the same methodology but in an adequate sample of cases, found a false negative result of the UBT in 1.8% (n=3) of the patients (n=167). This datum demonstrates that the breath test is altered in a minimal percentage of patients who have received previous treatment with almagate at the usual recommended doses and confirms the results of the aforementioned pilot study.¹²

Other factors that cause the test to yield a small percentage of false negatives¹⁷ are fasting time (at least eight hours before the test) and the duration of the treatment with the drug potentially causing the interference.²⁹

In our study, it should be noted that two other patients who had also been exposed to ranitidine were not false negatives since one of them tested positive in the first UBT and the other, negative, was confirmed as such in the second.

It is worth analysing the three patients classified as false negatives for almagate the present study who were from the same site. One of them had also taken ranitidine, which could have influenced the test result (although the kit used has citric acid and a high concentration of urea). Therefore, it is difficult to conclude to which treatment, the antacid or the ranitidine, we should attribute

responsibility for the false negative. The second false negative can be accounted for by data from the medical history which showed that eradication therapy had been given a few years previously, although the eradication had not been verified and had therefore probably not been achieved. The third case had received eradication therapy some years previously, and the first UBT result was negative (with a delta of 4, limit) that turned positive (delta of 8) in the second UBT, bringing up the question of the limit values between 2 and 5. Although the test's cut-off point is 5, the positive and negative results of the UBT have been seen to lie outside the range of 2/1000 and 5/1000, indicating that the values between 2 and 5 should be confirmed.³⁰

The study's limitations include its observational nature, rendering it more susceptible to possible interference from confounding factors. Furthermore, by including patients who had been previously diagnosed and who therefore had possibly already undergone treatment and eradication, the prevalence of infection in the sample is reduced. As prevalence diminishes, a positive result will not allow confirmation of the diagnosis, and these positives were not confirmed with any other reference test. This would affect the PPV, which may be lower than expected. However, in view of the results of this study, which are very similar to the pilot study, and considering that the sample size is adequate, we believe that it can be asserted that almagate does not significantly interfere with the result of the UBT.

Conclusions

In conclusion, almagate does not interfere with or has a minimal interference in the result of the breath test for the diagnosis of *H. pylori* infection. Almagate is a pharmacological alternative for treating the symptoms that patients present in the weeks before the breath test, during which PPI treatment must be suspended a minimum of two weeks before the UBT test to assess whether or not they are infected with *H. pylori*.

Conflicts of interest

This work was funded by Almirall, S.A., Barcelona and it has also been made possible thanks to the contribution of complimentary urea tests by Isomed Pharma (100 mg ¹³C TAUKIT kit).

Dr Gisbert has provided scientific advice, support to research and/or training activities for the Mayoly, Allergan and DiaSorin companies. Doctors Pons, Varas and Barenys have no conflicts of interest. Doctors Pajuelo and Fernández are employees of Almirall.

Acknowledgements

We would also like to acknowledge the participation of the following principal investigators at their reference centres: Dr Josep Merlo Mas (Centre Medicoquirúrgic Servidigest), Dr Llúcia Titó (Hospital de Mataró [Mataró Hospital]), Dr Josep María Botargues (Hospital Bellvitge), Dr José A. Pajares Díaz (Hospital Gregorio Marañón [Gregorio Marañón Hospital]).

Esther Parramón Altarriba from Hospital CIMA Sanitas [Sanitas CIMA Hospital] in Barcelona carried out the UBT tests at that centre.

Almudena Pardo Mateos, PhD, contributed *medical writing*, which was financed by Almirall, S.A.

References

- Leja M, Grinberga-Derica I, Bilgili C, Steininger C. Review: epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 2019;24:e12635, <http://dx.doi.org/10.1111/hel.12635>.
- Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of *Helicobacter pylori* infection. *Helicobacter*. 2014;19:1–5, <http://dx.doi.org/10.1111/hel.12165>.
- Baena Diez JM, Garcia Lareo M, Marti Fernandez J, Leon Marin I, Muniz Llama D, Teruel Gila J, et al. [Prevalence of *Helicobacter pylori* infection in primary care: sero-epidemiological study]. *Aten Primaria*. 2002;29:553–7, [http://dx.doi.org/10.1016/s0212-6567\(02\)70636-7](http://dx.doi.org/10.1016/s0212-6567(02)70636-7).
- Sanchez Ceballos F, Taxonera Samso C, Garcia Alonso C, Alba Lopez C, Sainz de Los Terreros Soler L, Diaz-Rubio M. [Prevalence of *Helicobacter pylori* infection in the healthy population of Madrid (Spain)]. *Rev Esp Enferm Dig*. 2007;99:497–501, <http://dx.doi.org/10.4321/s1130-01082007000900003>.
- Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of *Helicobacter pylori* infection — a critical review. *Aliment Pharmacol Ther*. 2004;20:1001–17, <http://dx.doi.org/10.1111/j.1365-2036.2004.02203.x>.
- Leung WK, Hung LC, Kwok CK, Leong RW, Ng DK, Sung JJ. Follow up of serial urea breath test results in patients after consumption of antibiotics for non-gastric infections. *World J Gastroenterol*. 2002;8:703–6, <http://dx.doi.org/10.3748/wjg.v8.i4.703>.
- Manes G, Balzano A, Iaquinto G, Ricci C, Piccirillo MM, Giardullo N, et al. Accuracy of the stool antigen test in the diagnosis of *Helicobacter pylori* infection before treatment and in patients on omeprazole therapy. *Aliment Pharmacol Ther*. 2001;15:73–9, <http://dx.doi.org/10.1046/j.1365-2036.2001.00907.x>.
- Graham DY, Opekun AR, Jogi M, Yamaoka Y, Lu H, Reddy R, et al. False negative urea breath tests with H₂-receptor antagonists: interactions between *Helicobacter pylori* density and pH. *Helicobacter*. 2004;9:17–27, <http://dx.doi.org/10.1111/j.1083-4389.2004.00191.x>.
- Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia. *Cochrane Database Syst Rev*. 2017;3:CD011194, <http://dx.doi.org/10.1002/14651858.CD011194.pub2>.
- Morales Suarez-Varela MM, Perez-Benajas MA, Girbes Pelechano VJ, Llopis-Gonzalez A. Antacid (A02A) and antiulcer (A02B) drug prescription patterns: predicting factors, dosage and treatment duration. *Eur J Epidemiol*. 1998;14:363–72, <http://dx.doi.org/10.1023/a:1007493003891>.
- Ficha Técnica Almax. AEMPS; 2018.
- Pons C, Maisterra S, Salord S, Pla A, Asensio D, Fernandez FJ, et al. Almagate interference in breath test results for the diagnosis of *Helicobacter pylori* infection. *Rev Esp Enferm Dig*. 2014;106:448–51.
- Perez-Grueso Macias MJ, Valle Munoz J, Gonzalez de Frutos C, Artaza Varasa T, Rodriguez-Merlo R, Alcantara Torres M, et al. [Clinicopathological characteristics of uninvestigated dyspepsia in Spain]. *Gastroenterol Hepatol*. 2007;30:1–6, <http://dx.doi.org/10.1157/13097442>.
- Alcedo J, Guevara T, Mearin F. Sección 1. Síntomas Gastrointestinales Frecuentes. Capítulo 3. El enfermo con dispepsia. In: Montoro MA, García Pagán JC, editors. *Problemas Comunes en la Práctica Clínica - Gastroenterología y Hepatología*. 2nd ed Asociación Española de Gastroenterología (AEG); 2012. p. 37–60.
- Kim SE, Park HK, Kim N, Joo YE, Baik GH, Shin JE, et al. Prevalence and risk factors of functional dyspepsia: a nationwide multicenter prospective study in Korea. *J Clin Gastroenterol*. 2014;48:e12–8, <http://dx.doi.org/10.1097/MCG.0b013e31828f4bc9>.
- Harmon RC, Peura DA. Evaluation and management of dyspepsia. *Therap Adv Gastroenterol*. 2010;3:87–98, <http://dx.doi.org/10.1177/1756283X09356590>.
- Gisbert JP, Ducons J, Gomollon F, Dominguez-Munoz JE, Borda F, Mino G, et al. Validation of the 13c-urea breath test for the initial diagnosis of *Helicobacter pylori* infection and to confirm eradication after treatment. *Rev Esp Enferm Dig*. 2003;95:121–6.
- Pantoflickova D, Scott DR, Sachs G, Dorta G, Blum AL. 13C urea breath test (UBT) in the diagnosis of *Helicobacter pylori*: why does it work better with acid test meals? *Gut*. 2003;52:933–7, <http://dx.doi.org/10.1136/gut.52.7.933>.
- Best LM, Takwoingi Y, Siddique S, Selladurai A, Gandhi A, Low B, et al. Non-invasive diagnostic tests for *Helicobacter pylori* infection. *Cochrane Database Syst Rev*. 2018;3:CD012080, <http://dx.doi.org/10.1002/14651858.CD012080.pub2>.
- McNicholl AG, Garre A, Llorca L, Bujanda L, Molina-Infante J, Barenys M, et al. Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum HpSA and novel ImmunoCard STAT! rapid test) for the diagnosis of *Helicobacter pylori* infection. *Gastroenterol Hepatol*. 2019, <http://dx.doi.org/10.1016/j.gastrohep.2019.09.009>.
- Gisbert JP, Calvet X, Bermejo F, Boixeda D, Bory F, Bujanda L, et al. [III Spanish Consensus Conference on *Helicobacter pylori* infection]. *Gastroenterol Hepatol*. 2013;36:340–74, <http://dx.doi.org/10.1016/j.gastrohep.2013.01.011>.
- Parente F, Sainaghi M, Sangaletti O, Imbesi V, Maconi G, Anderloni A, et al. Different effects of short-term omeprazole, lansoprazole or pantoprazole on the accuracy of the (13)C-urea breath test. *Aliment Pharmacol Ther*. 2002;16:553–7, <http://dx.doi.org/10.1046/j.1365-2036.2002.01192.x>.
- Levine A, Shevah O, Shabat-Sehayek V, Aeed H, Boaz M, Moss SF, et al. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. *Aliment Pharmacol Ther*. 2004;20:117–22, <http://dx.doi.org/10.1111/j.1365-2036.2004.02021.x>.
- Connor SJ, Ngu MC, Katelaris PH. The impact of short-term ranitidine use on the precision of the 13C-urea breath test in subjects infected with *Helicobacter pylori*. *Eur J Gastroenterol Hepatol*. 1999;11:1135–8, <http://dx.doi.org/10.1097/00042737-199910000-00010>.
- Savarino V, Tracci D, Dulbecco P, Mele MR, Zentilin P, Mansi C, et al. Negative effect of ranitidine on the results of urea breath test for the diagnosis of *Helicobacter pylori*. *Am J Gastroenterol*. 2001;96:348–52, <http://dx.doi.org/10.1111/j.1572-0241.2001.03517.x>.
- Gisbert JP, Pajares JM. 13C-urea breath test in the management of *Helicobacter pylori* infection. *Dig Liver Dis*. 2005;37:899–906, <http://dx.doi.org/10.1016/j.dld.2005.09.006>.
- Beckett PR, Lluvia J, Lumachi B, Roberts DJ. Pharmacological studies with almagate, a potent new antacid compound. *Arzneimittelforschung*. 1984;34:1367–70.
- Gatta L, Vakil N, Ricci C, Osborn JF, Tampieri A, Perna F, et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for *Helicobacter pylori* infection. *Am J Gastroenterol*. 2004;99:823–9, <http://dx.doi.org/10.1111/j.1572-0241.2004.30162.x>.

29. TAU-KIT. Isomed Pharma. Available from: <https://www.isomed.com/index.php/en/products/taukit/89-taukit/>. [cited 2020 Feb.17th].
30. Gisbert JP, Olivares D, Jimenez I, Pajares JM. Long-term follow-up of 13C-urea breath test results after *Helicobacter pylori* eradication: frequency and significance of borderline delta13CO2 values. Aliment Pharmacol Ther. 2006;23:275–80, <http://dx.doi.org/10.1111/j.1365-2036.2006.02741.x>.